Overview

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Status:
Recruiting
Trial end date:
2023-12-07
Target enrollment:
Participant gender:
Summary
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals